FBT

First Trust NYSE Arca Biotechnology Index Fund

Down$125.63
$-0.58
(-0.46%)
As of 12:00:00 AM EDT | 10/18/19  |  Market Closed

FBT Trading Data

Open

$125.92

Low Price

$124.41

High Price

$127.02

Previous Last Price

$126.21

Bid Size

$0 X 0

Ask Size

$0 X 0

FBT Portfolio Data

AUM

$1,629,399,000

Shares

12,900

PE Ratio

19.68

Price / Book Ratio

4.78

Expense Ratio

0.57

Net Asset Value

$126.31

Volume

Volume

100,900

Avg. Volume (YDT)

175,634

Dollar Volume

$0

Weekly Avg. Volume

102,940

Monthly Avg. Volume

143,860

Quarterly Avg. Volume

254,154

FBT Fund Description

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July and October to ensure that each component stock continues to represent approximately equal weight in the index.

FBT Chart

FBT Summary

Fund Family

First Trust Portfolios

Tracks This Index

First Trust NYSE Arca Biotechnology Index Fund

Inception Date

2006-06-19

Asset Class

Equity

Asset Class Size

Biotech

FBT Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

FBT Holdings

Top 10 Holdings

First Trust NYSE Arca Biotechnology Index Fund (FBT)
0%
ACADIA Pharmaceuticals Inc. (ACAD)
0%
Amgen Inc. (AMGN)
0%
Seattle Genetics Inc. (SGEN)
0%
United Therapeutics Corporation (UTHR)
0%
Illumina Inc. (ILMN)
0%
Neurocrine Biosciences Inc. (NBIX)
0%
Alnylam Pharmaceuticals Inc. (ALNY)
0%
Regeneron Pharmaceuticals Inc. (REGN)
0%
Vertex Pharmaceuticals Incorporated (VRTX)
0%

Total FBT Holdings

Total Holdings: 32

First Trust NYSE Arca Biotechnology Index Fund (FBT)
0%
ACADIA Pharmaceuticals Inc. (ACAD)
0%
Amgen Inc. (AMGN)
0%
Seattle Genetics Inc. (SGEN)
0%
United Therapeutics Corporation (UTHR)
0%
Illumina Inc. (ILMN)
0%
Neurocrine Biosciences Inc. (NBIX)
0%
Alnylam Pharmaceuticals Inc. (ALNY)
0%
Regeneron Pharmaceuticals Inc. (REGN)
0%
Vertex Pharmaceuticals Incorporated (VRTX)
0%
Gilead Sciences Inc. (GILD)
0%
Charles River Laboratories International Inc. (CRL)
0%
Biogen Inc. (BIIB)
0%
Incyte Corporation (INCY)
0%
Bio-Techne Corporation (TECH)
0%
IQVIA Holdings Inc. (IQV)
0%
Grifols S.A. (ADR) (GRFS)
0%
Ionis Pharmaceuticals Inc. (IONS)
0%
Intercept Pharmaceuticals Inc. (ICPT)
0%
Alexion Pharmaceuticals Inc. (ALXN)
0%
Exact Sciences Corporation (EXAS)
0%
BioMarin Pharmaceutical Inc. (BMRN)
0%
FibroGen Inc. (FGEN)
0%
Alkermes Plc (ALKS)
0%
Exelixis Inc. (EXEL)
0%
Agios Pharmaceuticals Inc. (AGIO)
0%
QIAGEN N.V. (QGEN)
0%
Ultragenyx Pharmaceutical Inc. (RARE)
0%
bluebird bio Inc. (BLUE)
0%
Sarepta Therapeutics Inc. (SRPT)
0%
Nektar Therapeutics (NKTR)
0%
US Dollar ($USD)
0%

FBT Technicals

Alpha

-2.16

Beta

1.49

Leverage

Long

Standard Deviation

8.39

FBT Dividends

Dividend Date

2015-09-23

Latest Dividend

0.02

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

FBT Performance

YTD Return

1.15%

1 Year Return

-14.2%

3 Year Return

38.94%

5 Year Return

30.57%

10 Year Return

403.93%

FBT Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.